Diadema Partners »

Skye Bioscience shares owned by Diadema Partners

Quarter-by-quarter ownership of Skye Bioscience (SKYE) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Skye Bioscience

Tip: Access up to 7 years of quarterly data

All positions including Skye Bioscience held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Skye Bioscience by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.2M 300k 3.93

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding Skye Bioscience

5AM Venture Management
Versant Venture Management
Baker Bros. Advisors
Schonfeld Strategic Advisors
Vanguard Group
Ensign Peak Advisors
Driehaus Capital Management
Sphera Funds Management
Alyeska Investment Group
Millennium Management
Diadema Partners
BlackRock
Mirae Asset Global Etfs Holdings
Marshall Wace
Platinum Investment Mangement

View all funds holding Skye Bioscience